Infants aged 6-7 weeks were randomly assigned ( 2:1 ) , via a central interactive voice or web response system with a block size of 12 , to receive either three doses of oral human-bovine natural reassortant vaccine ( 116E ) or placebo at ages 6-7 weeks , 10 weeks , and 14 weeks .